Human mannose-binding lectin inhibitor prevents Shiga toxin–induced renal injury

Kidney International

Volumn 90, Issue 4, 2016, Pages 774-782

  Ozaki, Masayuki ^a,b   Kang, Yulin ^a   Tan, Ying Siow ^a   Pavlov, Vasile I ^a   Liu, Bohan ^c   Boyle, Daniel C ^c   Kushak, Rafail I ^c   Skjoedt, Mikkel Ole ^a,d   Grabowski, Eric F ^c   Taira, Yasuhiko ^b   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d University of Copenhagen   (Denmark)

Author keywords

antibody; complement activation; deposition; fibrin; lectin pathway

Indexed keywords

COMPLEMENT COMPONENT C3D; FIBRIN; HEMOGLOBIN; MANNOSE BINDING LECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; SHIGA TOXIN; UNCLASSIFIED DRUG; 3F8 ANTIBODY; IMMUNOGLOBULIN G; MANNOSE BINDING PROTEIN A; MBL2 PROTEIN, HUMAN; MBL2 PROTEIN, MOUSE; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DOSE RESPONSE; FIBRIN DEPOSITION; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC UREMIC SYNDROME; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RENAL PROTECTION; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENE TARGETING; GENETICS; HEMOLYTIC-UREMIC SYNDROME; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; COMPLEMENT C3D; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI INFECTIONS; GENE KNOCK-IN TECHNIQUES; GLOMERULAR FILTRATION RATE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MANNOSE-BINDING LECTIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SHIGA TOXIN 2; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 85003678427     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.05.011     Document Type: Article

References (66)

1. 1 Tarr, P.I., Gordon, C.A., Chandler, W.L., Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365 (2005), 1073–1086.
2. 2 O'Brien, A.D., LaVeck, G.D., Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun 40 (1983), 675–683.
3. 3 Butler, T., Haemolytic uraemic syndrome during shigellosis. Trans R Soc Trop Med Hyg 106 (2012), 395–399.
4. 4 Bitzan, M., Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl, 2009, S62–S66.
5. 5 Spinale, J.M., Ruebner, R.L., Copelovitch, L., et al. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 28 (2013), 2097–2105.
6. 6 Sharma, A.P., Filler, G., Dwight, P., et al. Chronic renal disease is more prevalent in patients with hemolytic uremic syndrome who had a positive history of diarrhea. Kidney Int 78 (2010), 598–604.
7. 7 Walsh, M.J., Dodd, J.E., Hautbergue, G.M., Ribosome-inactivating proteins: potent poisons and molecular tools. Virulence 4 (2013), 774–784.
8. 8 Scotland, S.M., Willshaw, G.A., Smith, H.R., et al. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect 99 (1987), 613–624.
9. 9 Morigi, M., Galbusera, M., Gastoldi, S., et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187 (2011), 172–180.
10. 10 Endo, Y., Tsurugi, K., Yutsudo, T., et al. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171 (1988), 45–50.
11. 11 Grabowski, E.F., Liu, B., Gerace, M.R., et al. Shiga toxin-1 decreases endothelial cell tissue factor pathway inhibitor not co-localized with tissue factor on the cell membrane. Thromb Res 135 (2015), 1214–1217.
12. 12 Grabowski, E.F., Kushak, R.I., Liu, B., et al. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium. Thromb Res 131 (2013), 521–528.
13. 13 Jandhyala, D.M., Thorpe, C.M., Magun, B., Ricin and Shiga toxins: effects on host cell signal transduction. Curr Top Microbiol Immunol 357 (2012), 41–65.
14. 14 Noris, M., Mescia, F., Remuzzi, G., STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8 (2012), 622–633.
15. 15 Cameron, J.S., Vick, R., Letter: plasma-C3 in haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura. Lancet, 2, 1973, 975.
16. 16 Robson, W.L., Leung, A.K., Fick, G.H., et al. Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. Nephron 62 (1992), 296–299.
17. 17 Monnens, L., Molenaar, J., Lambert, P.H., et al. The complement system in hemolytic-uremic syndrome in childhood. Clin Nephrol 13 (1980), 168–171.
18. 18 Thurman, J.M., Marians, R., Emlen, W., et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4 (2009), 1920–1924.
19. 19 Stahl, A.L., Sartz, L., Karpman, D., Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117 (2011), 5503–5513.
20. 20 Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364 (2011), 2561–2563.
21. 21 Kielstein, J.T., Beutel, G., Fleig, S., et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27 (2012), 3807–3815.
22. 22 Menne, J., Nitschke, M., Stingele, R., et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ, 345, 2012, e4565.
23. 23 Gulla, K.C., Gupta, K., Krarup, A., et al. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology 129 (2010), 482–495.
24. 24 Hess, K., Ajjan, R., Phoenix, F., et al. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One, 7, 2012, e35690.
25. 25 La Bonte, L.R., Pavlov, V.I., Tan, Y.S., et al. Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 188 (2012), 885–891.
26. 26 Pavlov, V.I., Skjoedt, M.O., Siow, T.Y., et al. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 126 (2012), 2227–2235.
27. 27 Collard, C.D., Vakeva, A., Morrissey, M.A., et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 156 (2000), 1549–1556.
28. 28 Zhao, H., Wakamiya, N., Suzuki, Y., et al. Identification of human mannose binding lectin (MBL) recognition sites for novel inhibitory antibodies. Hybrid Hybridomics 21 (2002), 25–36.
29. 29 Pavlov, V.I., Tan, Y.S., McClure, E.E., et al. Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model. Am J Pathol 185 (2015), 347–355.
30. 30 Keepers, T.R., Psotka, M.A., Gross, L.K., et al. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. J Am Soc Nephrol 17 (2006), 3404–3414.
31. 31 Sauter, K.A., Melton-Celsa, A.R., Larkin, K., et al. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect Immun 76 (2008), 4469–4478.
32. 32 Petruzziello-Pellegrini, T.N., Yuen, D.A., Page, A.V., et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 122 (2012), 759–776.
33. 33 Acheson, D.W., Jacewicz, M., Kane, A.V., et al. One step high yield affinity purification of Shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays. Microb Pathog 14 (1993), 57–66.
34. 34 Wen, S.X., Teel, L.D., Judge, N.A., et al. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24 (2006), 1142–1148.
35. 35 Sheerin, N.S., Risley, P., Abe, K., et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J 22 (2008), 1065–1072.
36. 36 Zhou, W.D., Marsh, J.E., Sacks, S.H., Intrarenal synthesis of complement. Kidney Int 59 (2001), 1227–1235.
37. 37 Porubsky, S., Federico, G., Muthing, J., et al. Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol 234 (2014), 120–133.
38. 38 Paixao-Cavalcante, D., Botto, M., Cook, H.T., et al. Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. Clin Exp Immunol 155 (2009), 339–347.
39. 39 Locatelli, M., Buelli, S., Pezzotta, A., et al. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 25 (2014), 1786–1798.
40. 40 Obrig, T.G., Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins (Basel) 2 (2010), 2769–2794.
41. 41 Gallegos, K.M., Conrady, D.G., Karve, S.S., et al. Shiga toxin binding to glycolipids and glycans. PLoS One, 7, 2012, e30368.
42. 42 Arvidsson, I., Stahl, A.L., Hedstrom, M.M., et al. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. J Immunol 194 (2015), 2309–2318.
43. 43 Stahl, A.L., Arvidsson, I., Johansson, K.E., et al. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog, 11, 2015, e1004619.
44. 44 van der Pol, P., Schlagwein, N., van Gijlswijk, D.J., et al. Mannan-binding lectin mediates renal ischemia/reperfusion injury independent of complement activation. Am J Transplant 12 (2012), 877–887.
45. 45 Sandvig, K., van, D.B., Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J 19 (2000), 5943–5950.
46. 46 Gomez, S.A., Abrey-Recalde, M.J., Panek, C.A., et al. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol 173 (2013), 463–472.
47. 47 Tateishi, K., Matsushita, M., Activation of the alternative complement pathway by mannose-binding lectin via a C2-bypass pathway. Microbiol Immunol 55 (2011), 817–821.
48. 48 Iwaki, D., Kanno, K., Takahashi, M., et al. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 187 (2011), 3751–3758.
49. 49 Tedesco, F., Pausa, M., Nardon, E., et al. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 185 (1997), 1619–1627.
50. 50 Endo, Y., Nakazawa, N., Iwaki, D., et al. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J Innate Immun 2 (2010), 33–42.
51. 51 Bathum, L., Hansen, H., Teisner, B., et al. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 43 (2006), 473–479.
52. 52 Berger, S.P., Daha, M.R., Emerging role of the mannose-binding lectin-dependent pathway of complement activation in clinical organ transplantation. Curr Opin Organ Transplant 16 (2011), 28–33.
53. 53 Bouwman, L.H., Roos, A., Terpstra, O.T., et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 129 (2005), 408–414.
54. 54 Super, M., Thiel, S., Lu, J., et al. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 2 (1989), 1236–1239.
55. 55 Proulx, F., Wagner, E., Toledano, B., et al. Mannan-binding lectin in children with Escherichia coli O157:H7 haemmorrhagic colitis and haemolytic uraemic syndrome. Clin Exp Immunol 133 (2003), 360–363.
56. 56 Roos, A., Rastaldi, M.P., Calvaresi, N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17 (2006), 1724–1734.
57. 57 National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed, 2011, National Academies Press (US), Washington, DC.
58. 58 Walsh, M.C., Bourcier, T., Takahashi, K., et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 175 (2005), 541–546.
59. 59 Walsh, M.C., Shaffer, L.A., Guikema, B.J., et al. Fluorochrome-linked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. J Immunol Methods 323 (2007), 147–159.
60. 60 Sturgeon, C., Sam, A.D., Law, W.R., Rapid determination of glomerular filtration rate by single-bolus inulin: a comparison of estimation analyses. J Appl Physiol (1985) 84 (1998), 2154–2162.
61. 61 O'Brien, S.P., Smith, M., Ling, H., et al. Glomerulopathy in the KK.Cg-A(y) /J mouse reflects the pathology of diabetic nephropathy. J Diabetes Res, 2013, 2013, 498925.
62. 62 Tofukuji, M., Stahl, G.L., Agah, A., et al. Anti-C5a monoclonal antibody reduces cardioplegia-induced coronary endothelia dysfunction. J Thorac Cardiovasc Surg 116 (1998), 1060–1068.
63. 63 Weiler-Guettler, H., Christie, P.D., Beeler, D.L., et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 101 (1998), 1983–1991.
64. 64 Rangan, G.K., Tesch, G.H., Quantification of renal pathology by image analysis. Nephrology (Carlton) 12 (2007), 553–558.
65. 65 Lo, T.H., Tseng, K.Y., Tsao, W.S., et al. TREM-1 regulates macrophage polarization in ureteral obstruction. Kidney Int 86 (2014), 1174–1186.
66. 66 Satake, K., Shimizu, Y., Sasaki, Y., et al. Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. BMC Nephrol, 15, 2014, 89.